The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
That’s unfair Sharestack, I’m definitely not a fan of gammon.
Back in the olden days, it used to be based on who has a gentleman’s sausage and who doesn’t. There are apparently 72 gender identification and then I guess a list of ways that the dirty deed is performed by those genders.
No wonder it’s hard (no pun intended) to define the rules and how to summarise them.
Tygra……It made about as much sense as that garbage you just put on NCYT. What a weirdo you are!
Another weirdo turns up to spout nonsense, has no idea how PCRs work and hates medicine and doctors and scientists. Yet happy to invest in Russian assets in Poly which will suddenly going to delist at some point in the near future.
WBA ……valju is the last person you should listen to and absolutely clueless when it comes to a general understanding of the market. Most brokers do not lend out your shares so they won’t be used for shorts. If you ask your broker, they will clarify this to you. I’m certainly not saying buy, sell or hold as no one knows what will happen here. Others should not advise either, certainly on the very little information which Novacyt have given us.
Sorry wba but that is the complete wrong advice to give.
The ones who are strong and keep hold of their shares are the ones on massive losses right now. The weak ones (let’s call them) sold out and reduced their losses. Don’t get caught up in the nonsense that gets spouted on bb’s. I’ve invested for 20 years in different markets. AIM is nothing but a massive risk and one which we are find out ourselves in now unfortunately. We just need to hope for a miracle as no one knows what the sp will be in 2 years time. It could be 20p or £10.
Possibly got stung in the past here WBA like the rest of us. Worth remembering that’s what a lot of people accused you of also doing many times. Sometimes you just have to accept that people vent here and not based on silly conspiracy theories.
@kilkennyTed
No I didn’t did I.
I’ll go with Larry10s reply that he gave on 20 Jul 2022 @13:24…….it’s personal.
DRB83…..you said you are not sure why the LTIP second and third tranches were delayed?
I would hope that the remuneration committee along with DA put a hold on the payments until the formal outcome of the DHSC dispute. The share price would never have reached that price if facts relating to the second DHSC contract being at dispute had been communicated. Even if you say they didn’t know until 2021, the fact is GM and AD have been awarded against a disputed figure of £130m - how can that be fair, right or ethical or even deserving?
“but some of the comments on here, are making mine look intelligent! :)”
That’s a complete lie Valju, I’ve not seen a single comment in like forever that makes any of your comments look intelligent.
Well that’s one good thing Captain. We certainly won’t lose any big orders with only £3.5m of non-covid revenue in h1 2022 and with covid revenue all but dried up!
Did you know that this company had revenues of £7.223m in h1 2019 vs £3.5m in 2022.
H1 2018 - £6.427m
H1 2019 - £7.223m
H1 2020 -
H1 2021 - £4.600m
H1 2022 - £3.500m
That’s how poor this company is and how poor its leadership is. Understandable the drop off in covid peak times but in 2022 is disgusting results by DA.
Boeing have some great engineers but £19bn loss on max 737 and massive losses from reputation and cancelled orders has had a huge impact on the company and wiped half of the company MCAP away (£90bn).
B2…..if we lose and DHSC win, the sp will drop heavily whatever wording is used. The reputation damage along with DHSC payment would destroy Novacyt.
Agree Pi100. Sick of hearing it’s all priced in too. If we got an RNS tomorrow saying that the counter claim has been unsuccessful, the share price would drop 60 percent on open.
You haven’t used the the little green box though have you, you belter! After saying multiple times that you will green bin me yet you still love reading my comments.
Harchris….are you aware that DA now has a 3 year tenure? So if he fails, another CEO would be appointed after getting voted out then. The new one then gets his 1 year grace period to understand the business and then turn it around if he’s any good.
So shall we wait here until 2027 just to see what happens? I’m not sure I could listen to another 5 years of Valju.
Perhaps by then he will have been taken away in a straight jacket, muttering the words of “MM manipulation”, “I can wait forever”, I’m still buying down here” and “why in the 2027 are my buys still showing red” and “it’s all manipulation, in the green box with you, I love covid, covid4ever”, or words to that effect ……
And if a new CEO comes in after DA and he’s no good then we will then have millions for a newer newer ceo. And if that fails, we will have hundreds of thousands for the newer newerdy new ceo. And by then (2050) the next pandemic will be hitting us hard (but unfortunately we will be contending with 20 years of nuclear fallout from Putin).
Hey but 2100, I just know that this company can reach the dizzy heights of £1.20 a share by then.
GLA
Come on guys, at least read the annual report - it’s all in there:-
Going concern
Full payment of the remaining Long-Term Incentive Plan (“LTIP”) that commenced in November 2017 and vested in November 2020;
• Payment of the final earn-out milestone related to the IT-IS International acquisition;
AND
Notes to the Annual Accounts continued
3. Summary of accounting policies applied by the Group
Long-Term Incentive Plan
Novacyt granted to certain employees shares under a long-term management incentive plan adopted on 1 November 2017.
The exercise price is set at the share price on the grant date and the options will be settled in cash. The options fully vested on the third anniversary of the grant date, 1 November 2020. The payment expenses are calculated under IFRS 2 “Share-Based Payments”. The accounting charge has been spread across the vesting period to reflect the services received and a liability recognised in the statement of financial position. Payment of the second tranche was not made in November 2021 and has been delayed until 2022.
AND
32. Trade and other liabilities (£11.224m)
The other liabilities balance relates to the second and third tranches of the 2017 to 2020 LTIP scheme, which are forecast to be paid during 2022.
AND
35. Other liabilities long-term
The 2020 “other liabilities long-term” balance related to the third tranche of the 2017 to 2020 LTIP scheme that is due to be paid in November 2022 and has now moved to short-term liabilities as shown in note 32.
DrB83……will the LTIP, stocks or taxes etc need to be paid out of that £99.6m cash ……or are you saying that it is entirely a float with no liabilities against any of it?
Kaeren…….yes the global market damaged the sp but the biggest falls were well before the global falls from Russia. Let’s not pretend that the main falls are largely due to the company boards incompetence.